Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Harmony Biosciences Holdings (HRMY) Net Margin (2020 - 2025)

Harmony Biosciences Holdings' Net Margin history spans 6 years, with the latest figure at 9.22% for Q4 2025.

  • For Q4 2025, Net Margin fell 2373.0% year-over-year to 9.22%; the TTM value through Dec 2025 reached 18.27%, down 444.0%, while the annual FY2025 figure was 18.27%, 444.0% down from the prior year.
  • Net Margin for Q4 2025 was 9.22% at Harmony Biosciences Holdings, down from 21.24% in the prior quarter.
  • Across five years, Net Margin topped out at 75.03% in Q3 2022 and bottomed at 29.5% in Q4 2022.
  • The 5-year median for Net Margin is 22.99% (2022), against an average of 19.57%.
  • The largest annual shift saw Net Margin surged 25968bps in 2021 before it crashed -5440bps in 2022.
  • A 5-year view of Net Margin shows it stood at 24.9% in 2021, then crashed by -218bps to 29.5% in 2022, then skyrocketed by 154bps to 15.8% in 2023, then surged by 109bps to 32.95% in 2024, then tumbled by -72bps to 9.22% in 2025.
  • Per Business Quant, the three most recent readings for HRMY's Net Margin are 9.22% (Q4 2025), 21.24% (Q3 2025), and 19.84% (Q2 2025).